Targeting the Microtubule-Network Rescues CTL Killing Efficiency in Dense 3D Matrices

Efficacy of cytotoxic T lymphocyte (CTL)-based immunotherapy is still unsatisfactory against solid tumors, which are frequently characterized by condensed extracellular matrix. Here, using a unique 3D killing assay, we identify that the killing efficiency of primary human CTLs is substantially impai...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 729820
Main Authors Zhao, Renping, Zhou, Xiangda, Khan, Essak S, Alansary, Dalia, Friedmann, Kim S, Yang, Wenjuan, Schwarz, Eva C, Del Campo, Aránzazu, Hoth, Markus, Qu, Bin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Efficacy of cytotoxic T lymphocyte (CTL)-based immunotherapy is still unsatisfactory against solid tumors, which are frequently characterized by condensed extracellular matrix. Here, using a unique 3D killing assay, we identify that the killing efficiency of primary human CTLs is substantially impaired in dense collagen matrices. Although the expression of cytotoxic proteins in CTLs remained intact in dense collagen, CTL motility was largely compromised. Using light-sheet microscopy, we found that persistence and velocity of CTL migration was influenced by the stiffness and porosity of the 3D matrix. Notably, 3D CTL velocity was strongly correlated with their nuclear deformability, which was enhanced by disruption of the microtubule network especially in dense matrices. Concomitantly, CTL migration, search efficiency, and killing efficiency in dense collagen were significantly increased in microtubule-perturbed CTLs. In addition, the chemotherapeutically used microtubule inhibitor vinblastine drastically enhanced CTL killing efficiency in dense collagen. Together, our findings suggest targeting the microtubule network as a promising strategy to enhance efficacy of CTL-based immunotherapy against solid tumors, especially stiff solid tumors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Reviewed by: Shi Jiao, Fudan University, China; Yugang Guo, École Polytechnique Fédérale de Lausanne, Switzerland
Edited by: Li Tang, École Polytechnique Fédérale de Lausanne, Switzerland
This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.729820